Stock Quote
Gentium S.p.A. (GENT.W) (NASD ADF)
$2.28
9 Nov 2009
-13.31%
$2.63
$2.28
100
$2.28
$2.28
$4.00
$0.26
3.32
23,523
GENT.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Bellini, Francesco | Chairman of the Board | -- |
| Islam, Khalid | Interim Chief Executive Officer, Director | -- |
| Gemignani, Gary | Chief Financial Officer, Executive Vice President | -- |
Profile
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a deoxyribonucleic acid (DNA) based drug derived from pig intestines, to treat and prevent a disease called hepatic veno-occlusive disease (VOD), a condition in which some of the veins in the... Full Description
Company Address
Gentium S.p.A.
Piazza XX Settembre 2
Villa Guardia (Como) 22079
P: +39031.385217
F: +39031.385241
Piazza XX Settembre 2
Villa Guardia (Como) 22079
P: +39031.385217
F: +39031.385241
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Genzyme Corporation | $50.24 | +0.19 |
| Eisai Co., Ltd | ¥3,210.00 | +10.00 |
| Celgene Corporation | $55.65 | +0.74 |
| GENT.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 3.19 | 29.90 |
| ROI(TTM) | -73.46 | 2.35 |
| ROE(TTM) | -95.54 | 3.59 |
| Consensus Recommendation | |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -- |
| Total Revenue | $3.87M |
| Net Income | $-0.72M |
| EPS | $-0.05 |
